There are no disease-modifying treatments for adult human neurodegenerative diseases. Here we test RNA-targeted therapies 1 in two mouse models of spinocerebellar ataxia type 2 (SCA2), an autosomal dominant polyglutamine disease 2 . Both models recreate the progressive adult-onset dysfunction and degeneration of a neuronal network that are seen in patients, including decreased firing frequency of cerebellar Purkinje cells and a decline in motor function 3,4 . We developed a potential therapy directed at the ATXN2 gene by screening 152 antisense oligonucleotides (ASOs). The most promising oligonucleotide, ASO7, downregulated ATXN2 mRNA and protein, which resulted in delayed onset of the SCA2 phenotype. After delivery by intracerebroventricular injection to ATXN2-Q127 mice, ASO7 localized to Purkinje cells, reduced cerebellar ATXN2 expression below 75% for more than 10 weeks without microglial activation, and reduced the levels of cerebellar ATXN2. Treatment of symptomatic mice with ASO7 improved motor function compared to saline-treated mice. ASO7 had a similar effect in the BAC-Q72 SCA2 mouse model, and in both mouse models it normalized protein levels of several SCA2-related proteins expressed in Purkinje cells, including Rgs8, Pcp2, Pcp4, Homer3, Cep76 and Fam107b. Notably, the firing frequency of Purkinje cells returned to normal even when treatment was initiated more than 12 weeks after the onset of the motor phenotype in BAC-Q72 mice. These findings support ASOs as a promising approach for treating some human neurodegenerative diseases.
biochemical and physiological studies. This ASO targets exon 11 of human ATXN2 and is designated ASO7.
In a previous study using mice that were homozygous for the polyQ-expanded ATXN2, a more severe disease manifestation was observed than in heterozygous littermate mice, indicating that ATXN2 dosage was important pathologically 8 . On the other hand, reducing ATXN2 dosage did not affect survival or central nervous system morphology in heterozygous or homozygous knockout animals 9 , suggesting ATXN2 reduction by ASOs as a viable strategy for SCA2-mediated neurodegeneration.
Our in vitro screen included 152 ASOs designed in silico for targeting human ATXN2. The top 8 lead ASOs lowered ATXN2 expression by ≥ 85% (Extended Data Fig. 1 and Supplementary Table 1 ). In vivo testing revealed ASO7 and two other ASOs among the most effective for lowering ATXN2 expression after a seven day treatment (Extended Data Fig. 2a -c). To assess astroglial and microglial activation we measured cerebellar Gfap and Aif1 expression by qPCR. We tested several doses of ASO7 and observed a significant reduction in ATXN2 in cerebella after 14 days of treatment with 210 μ g ASO7 without activation of Gfap or Aif1 (Extended Data Figs 2a-c, 3). Some ASOs were not further pursued owing to activation of astroglial or microglial responses in treatments over 10 weeks. We verified that ASO7 as well as other lead ASOs were taken up by Purkinje cells by immunohistochemistry (Extended Data Fig. 2d -i).
ATXN2-Q127 mice have a human ATXN2 cDNA transgene with 127 CAG repeats. We treated ATXN2-Q127 mice by intracerebroventricular injection (ICV) at 8 weeks of age, coinciding with the age of motor phenotype onset 4 , with ASO7 and tested motor performance on the accelerating rotarod at weeks 5, 9 and 13 after ICV injection. Consensus criteria for the conduct of preclinical trials were closely followed (see Supplementary Discussion). Progression of motor dysfunction in saline-treated mice was as previously observed 4 . Mice injected with ASO7 had significantly improved motor performance compared to saline-treated control mice (Fig. 1a ), and human ATXN2 and mouse Atxn2 mRNA levels were reduced by 75% and 20%, respectively, after motor phenotype testing, demonstrating target engagement ( Fig. 2a-c) .
In preclinical studies, it is important to test compounds in multiple models of the human disease. We therefore developed a mouse model that replicated the human disease more closely by expressing a bacterial-artificial-chromosome (BAC) transgene incorporating the human promoter as well as all exons, introns and flanking regions. The BAC resulted in expression of ATXN2 with 72 glutamines (Q72) in multiple neuronal tissues including the spinal cord 3 . The BAC-Q72 model approximates human disease not only with regard to disease manifestation and less pronounced progression, but also because it contains the entire human gene in its proper intronic-exonic context. We conducted an additional preclinical trial in this mouse model with treatment that was initiated at 8 weeks of age, as for the experiment using ATXN2-Q127 mice. Again, the mutated human ATXN2 and mouse Atxn2 were engaged by ASO7 with mRNA levels that were reduced by 60% and 26%, respectively (Fig. 2d ), and human ATXN2 was not detected in cerebellar lysates from treated mice by western blotting ( Fig. 2e , f). Ten weeks after ICV injection, significant improvement in motor behaviour was seen in ASO7-treated mice compared to saline-injected mice (Fig. 1b ). However, the rotarod performance of the ASO7-treated mice did not perfectly mirror that of wild-type mice. This might indicate that additional treatment time would be necessary to more completely restore cerebellar function. Rotarod results observed were not affected by differences in mouse weights between the experimental groups (Extended Data Fig. 4 ).
Previously, we established transcriptome and protein profiles characterized by progressive changes in the course of degeneration in SCA2 mouse models 3 . To evaluate the effect of ASO7 on steady-state mRNA and protein levels we chose the top 6 mRNAs that showed the most significant changes in both mouse models 3 . Given that the ATXN2-Q127 model expresses the transgene specifically in Purkinje cells, we investigated genes significantly altered by SCA2 progression that are highly and specifically expressed in Purkinje cells: Rgs8, Pcp2, Pcp4, Cep76, Homer3 and Fam107b (ref. 3) . RGS proteins inhibit mGlur1 (ref. 10) , which is a positive regulator of Ca 2+ release from internal stores 11 . Because mGlur1 signalling is disrupted in SCA2 Purkinje cells leading to abnormal Ca 2+ release, mGlur1 regulation may also be a function of Rgs8 (refs 3,12) . mGlur1 is also regulated in Purkinje cells by Homer3 (ref. 13 ). Pcp2 is a regulator of G i/o -coupled receptors including the P-type Ca 2+ channel, which is important for sensorimotor control 14 . Loss of Pcp4 causes abnormal parallel fibre synapses in Purkinje cells 15 , and Cep76 is required for normal centriole function 16 . Fam107b and Rgs8 were identified as cerebellar hub genes week-old BAC-Q72 mice and wild-type (WT) littermates were treated with 175 μ g ASO7 or saline ICV and tested on the rotarod at the indicated ages. n = 13 and 13, for wild-type mice treated with ASO7 and saline, respectively; n = 11 and 14, for BAC-Q72 mice treated with ASO7 and saline, respectively. Values are mean ± s.e.m. Probabilities of significance were determined using the method of generalized estimating equations. * P < 0.05; * * P < 0.01; NS, not significant. LETTER RESEARCH with reduced expression in SCA1 mice 17 . Although significant increases at the mRNA level occurred for half of the genes after ASO7 treatment (Fig. 2) , we observed restored protein expression for all six of the genes on western blots (Fig. 2 , uncropped western blots in Supplementary  Fig. 1 ). This observation is consistent with an emerging role of polyglutamine-expanded ATXN2 in translational dysregulation 3, 18 .
Purkinje cells are neurons that fire spontaneously with a resting firing frequency of 40-50 Hz in mammals. The circuits that underlie cerebellar learning and functioning are well understood 12, 19, 20 , whereby the Purkinje cells integrate signals received from parallel and climbing fibres and provide the only output from cerebellar cortex to deep cerebellar nuclei. In acute slice preparations, we have previously shown that mutant ATXN2 caused a slowing of Purkinje cell firing. This change had an onset and progression that closely mirrored that of motor deficits with onset at 6-8 weeks and the firing rate eventual slowed to 20 Hz at 24 weeks of age 4 . It has been suggested that the change in the physiology of Purkinje cells is tightly linked to Ca 2+ homeostasis and subsequent cell death 12, 21 . This tight linkage between behaviour and physiology led us to hypothesize that ASO treatment would restore normal Purkinje cell firing. We injected ATXN2-Q127 mice at 8 weeks and analysed Purkinje cell physiology 6 and 14 weeks later in acute cerebellar slices. Similarly, we injected BAC-Q72 mice at 30 weeks, over 12 weeks after motor phenotype onset, and analysed Purkinje cell firing 10 weeks later. In both models, a single injection of ASO7 resulted in near complete restoration of normal Purkinje cell firing frequency (Figs 3, 4) . The mice used in these experiments were subsets of those in Fig. 1a, b , and had established rotarod phenotypes. These results suggest that ATXN2 ASO treatment directly affects Purkinje cell physiology and at least in part explains the amelioration of motor behaviour.
SCA2 and other polyglutamine diseases are characterized by toxic gains of function, suggesting that therapeutics that lower the expression of the disease-causing genes would be beneficial. ASOs represent an ideal approach for directly lowering ATXN2 expression, because ASOs are sequence-specific, well-tolerated, and can reach central nervous system targets by intrathecal delivery. Feasibility is further supported by an early-phase human clinical trial to develop an ASO therapy for SOD1-ALS 22 , and most recently by the FDA approval of the ASO drug nusinersin for spinal muscular atrophy. Various approaches to ASO therapeutics for polyglutamine diseases have been developed including targeting wild-type and mutant alleles as in this study or attempting to target mutant alleles through the expanded CAG repeat or through single nucleotide polymorphisms that are in linkage disequilibrium with the mutation 23, 24 . Deep cerebellar nuclei that were injected with adeno-associated viruses, which targeted shRNAs to Purkinje cells, were also effective for SCA1, reducing target expression and improving motor and cerebellar phenotypes in SCA1-transgenic mice 25, 26 . At least for SCA2 and with the caveats of preclinical mouse studies, the strategy of targeting both mutant and wild-type alleles is showing promise. One potential advantage of ASOs over current viral vectors is that they distribute through the nervous system, whereas adenoviral vectors are primarily transported transynaptically (also, gene transfer comes with more complex safety concerns). Therefore, for SCA2, adeno-associated viruses that are injected into neurons from the deep cerebellar nuclei would reach Purkinje cells, but may not reach other neuronal groups.
In conclusion, we rigorously screened ASOs to identify a potent and well-tolerated ASO, ASO7, that lowered cerebellar ATXN2 expression, and verified in two SCA2 models that ASO7 delayed SCA2 motor and electrophysiological phenotypes in replicate experiments. Cerebellar degenerative diseases provide excellent model systems to study the interaction of dysfunction in a neuronal network, behaviour and neurodegeneration. Our study suggests that reduction of mutant ATXN2 affects all three domains including endophenotypic markers of cell death common in ataxias 3, 17, 27 . Multiple lines of evidence suggest shown. d, The firing frequencies (mean ± s.e.m.) were 25 ± 2 Hz for the saline-treated mouse (n = 50 neurons, n = 1 mouse) and 46 ± 2 Hz for ASO7-treated mice (n = 88 neurons, n = 2 mice). e-h, ATXN2-Q127 mice were treated with 210 μ g ASO7 or saline by ICV injection at 8 weeks.
The firing frequency of Purkinje cells was evaluated at 22 weeks of age. e, Mean firing frequencies of all Purkinje cells measured from saline-and ASO7-treated mice and age-matched wild-type mice. f, g, Representative traces of 1 s duration of Purkinje cells (f) and interspike-interval histogram (g) of the same cell as in f, calculated for a 2 min duration, with values for the coefficient of variation shown. h, The firing frequencies (mean ± s.e.m.) were 16 ± 1 Hz for saline-treated ATXN2-Q127 mice (n = 107 neurons, n = 2 mice), 42 ± 2 Hz for the ASO7-treated ATXN2-Q127 mice (n = 102 neurons, n = 2 mice), and 40 ± 1 Hz for an age-matched wild-type mouse (n = 50 neurons, n = 1 mouse). All recordings were measured at 34.5 ± 1 °C. * * * * P < 0.0001, Student's t-test.
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that ASOs may have applications in human patients. ASO7 lowered expression of wild-type and mutant ATXN2 in SCA2 patient-derived fibroblasts (Extended Data Fig. 5 ). ASO7 delivered by ICV injection localized throughout the spinal column and lowered ATXN2 expression not only in brain, but also in spinal cord (data not shown). Notably, lowering of ATXN2 by ASO treatment or genetic knockout delays dysfunction and greatly extends survival of TDP-43 transgenic ALS mice. 28 . ASO7 or ASOs with further modifications in ASO chemistry may provide an effective human drug for SCA2, ALS caused by ATXN2 mutation and other forms of ALS. At 4 months the mean firing frequencies in Hz were 51 ± 2 for wild-type (n = 33 Purkinje cells, n = 1 mouse) and 54 ± 2 for BAC-Q72 (n = 59 Purkinje cells, n = 1 mouse). At 6 months the values were 41 ± 2 Hz for wild-type (n = 49 Purkinje cells, n = 2 mice) and 32 ± 1 Hz for BAC-Q72 (n = 101 Purkinje cells, n = 2 mice). At 12 months, values were 49 ± 2 Hz for wild-type (n = 55 Purkinje cells, n = 1 mouse) and 34 ± 1 for BAC-Q72 (n = 92 Purkinje cells, n = 1 mouse). h, ASO7 treatment restored the firing frequency of Purkinje cells from BAC-Q72 mice. The mean firing frequency of Purkinje cells from ten-month-old BAC-Q72 mice treated with saline was 36 ± 1 Hz (n = 148 Purkinje cells, n = 3 mice), whereas the mean firing frequency of BAC-Q72 mice treated with ASO7 was 49 ± 1 Hz (n = 134 Purkinje cells, n = 4 mice), similar to that of wild-type mice (49 ± 1 Hz, n = 155 Purkinje cells, n = 3 mice). * * * * P < 0.0001, ANOVA followed by Tukey's multiple-comparison post hoc testing.
